Ampio Pharma Announces Results from Panel Review of the Interim Analysis of the Optina(TM) Trial, FDA Agrees to 505(B) 2 Pathway

Ampio Pharmaceuticals, Inc.

today announced interim results from the ongoing 450 patient, dose finding, 505 (b) 2 study of OptinaTM as a treatment for Diabetic Macular Edema (DME). This interim analysis was conducted by an Independent Data Review Committee (IDRC) comprised of a statistician and an ophthalmologist/retinologist, who were permitted to view the unmasked data from the trial. At least thirty percent (30%) of patients had reached the first 4 week time point and their clinical results were considered representative data for the trial.  (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer explained:  "As is common with interim analyses of this sort, the analysis parameters were defined a priori and could have resulted in three possible scenarios as follows:  1) Termination of the study due to lack of efficacy or safety concerns, 2) delayed analysis if no conclusion could be drawn or 3) indication of an optimum dose if sufficient differentiation from placebo was present to indicate clinical benefit and no serious adverse events. The IDRC elected the third option and stated: "After a thorough review of the interim data from the ongoing study, it was determined that there was a